Cargando…

PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase

The mitotic kinase AURORA-A is essential for cell cycle progression and is considered a priority cancer target. While the catalytic activity of AURORA-A is essential for its mitotic function, recent reports indicate an additional non-catalytic function, which is difficult to target by conventional s...

Descripción completa

Detalles Bibliográficos
Autores principales: Adhikari, Bikash, Bozilovic, Jelena, Diebold, Mathias, Schwarz, Jessica Denise, Hofstetter, Julia, Schröder, Martin, Wanior, Marek, Narain, Ashwin, Vogt, Markus, Stankovic, Nevenka Dudvarski, Baluapuri, Apoorva, Schönemann, Lars, Eing, Lorenz, Bhandare, Pranjali, Kuster, Bernhard, Schlosser, Andreas, Heinzlmeir, Stephanie, Sotriffer, Christoph, Knapp, Stefan, Wolf, Elmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610535/
https://www.ncbi.nlm.nih.gov/pubmed/32989298
http://dx.doi.org/10.1038/s41589-020-00652-y
Descripción
Sumario:The mitotic kinase AURORA-A is essential for cell cycle progression and is considered a priority cancer target. While the catalytic activity of AURORA-A is essential for its mitotic function, recent reports indicate an additional non-catalytic function, which is difficult to target by conventional small molecules. We therefore developed a series of chemical degraders (PROTACs) by connecting a clinical kinase inhibitor of AURORA-A to E3 ligase-binding molecules (e.g. thalidomide). One degrader induced rapid, durable and highly specific degradation of AURORA-A. In addition ,we found that the degrader complex was stabilized by cooperative binding between AURORA-A and CEREBLON. Degrader-mediated AURORA-A depletion caused an S-phase defect, which is not the cell cycle effect observed upon kinase inhibition, supporting an important non-catalytic function of AURORA-A during DNA replication. AURORA-A degradation induced rampant apoptosis in cancer cell lines, and thus represents a versatile starting point for developing new therapeutics to counter AURORA-A function in cancer.